Navigation Links
Health Robotics Announces i.v.STATION(TM) Contract With Grifols in Spain, Portugal and South America
Date:6/29/2009

BOZEN , Italy, June 29 /PRNewswire/ -- Health-Robotics today announced that it has signed an exclusive 5-year strategic partnership with Grifols S.A., the leading Pharmacy Automation provider in Spain, Portugal, and South America. Grifols desires to safely, accurately, and cost-effectively automate the preparation of non-hazardous IV Admixtures with Health Robotics' i.v.STATION Robot. As part of this strategic partnership, Grifols will take delivery of 120 i.v.STATION Robots between now and December 2014 for deployment in Spain, Portugal, Chile, Brazil, Argentina, Uruguay, Paraguay, Peru, Ecuador, Bolivia, Venezuela, Colombia, Honduras, Costa Rica, Panama, El Salvador, Nicaragua, Guatemala, Surinam, Guyana, Belize, and French Guyana.

"We are very pleased to have been chosen by Health Robotics as their exclusive i.v.STATION partner in our core markets. i.v.STATION represents an ideal complement to other oral medication automation products such as BlisPack, Pyxis' MedStation, Kardex Carroussels, and to our systems for IV preparation as Misterium clean rooms or the Grifill sterile compounding device sector in which we hold a commanding lead in Spain, Portugal and South America with over 200 hospitals utilizing our Pharmacy Automation technology.

Grifols believes that i.v.STATION has the real potential to revolutionize Pharmacy Automation for IVs patient doses globally," stated Ramon Riera, Executive Member of the Board of Directors and Vice President of Marketing and Sales, Grifols.

i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost effective, and ready-to-administer IV Admixtures. Constructed around a scalable, distributed, and fail-safe architecture, i.v.STATION offers unprecedented final container flexibility, life-critical patient safety, and robotic precision and performance. i.v.STATION may be deployed in a variety of locations, including central and satellite pharmacies and direct patient care areas, due to its self-contained form, ISO Class 5 environment, and small "foot print". Pharmacies may, for the first time, choose a robotic configuration that suits their needs, rather than being forced into the dated alternative of "one-size-fits-all, million-dollar-plus" robots designed 10 years ago. Whether a Pharmacy chooses a single or multiple i.v.STATION configurations, it will benefit from fully automated compounding while producing its ready-to-administer IV doses in a variety of syringe, bag, vial, and tamper-evident caps from diverse medical suppliers.

"Grifols is everything we look for in a strategic partner for Health Robotics: company stability, world-class service infrastructure, well-developed marketing channels, and experience in IV therapy, clinical nutrition, and pharmacy automation. I was extremely impressed to see their manufacturing and biomedical expertise and the large footprint they have achieved with over 100 hospitals utilizing Pyxis MedStation technologies in their core markets. I hope this is just the beginning of a long-term partnership expanding into manufacturing and other unexplored fields in Robotics pharmacy automation such as total parenteral nutrition," stated Werner Rainer, Health Robotics' CEO.

About Health Robotics:

Health Robotics is the global leading supplier of life-critical intravenous medication preparation, compounding, and dispensing Robots, with fifty times more units sold that all of its competitors combined, and providing healthcare facilities in four continents with robotics technology and software automation solutions. The world-leading solutions CytoCare (hazardous IVs), i.v.STATION (non-hazardous IVs), and the current development of TPNstation (parenteral nutrition) have and will greatly contribute to ease global hospitals' and clinics' growing pressures to improve patient safety through the effective and efficient production of sterile, accurate, and ready-to-administer IVs, to eliminate life-threatening drug-exchange errors, to decrease other medication errors and contamination risks, and to work more efficiently, increase throughput, reduce waste, and contain costs.

About Grifols:

Grifols S.A. is a Spain-based company engaged in the healthcare sector and is listed on Ibex-35 stock market. Grifols is involved in the research, development, manufacturing and marketing of plasma derivates, IV therapy solutions, enteral and parenteral nutrition, diagnostic systems, pharmacy automation, and medical materials and devices. Founded in 1940, Grifols currently operates in 90 countries with more than 6.000 employees, 26 subsidiaries with combined gross revenues over euro 800 million, and a euro 3 billion market capitalization.

    For additional information, please contact:

    Health Robotics

    Gaspar G. DeViedma
    Altmanstrasse 9A, Bozen, Sud-Tyrol, I-39100
    USA: +1-609-980-7976
    Europe: +39-346-963-4934
    gaspar.deviedma@health-robotics.com

    Grifols
    Raquel Lumbreras
    Gabinete de Prensa Grifols
    Europe: +34-91-311-9289 / +91-221-7448 / +34-659-572-185
    Raquel_lumbreras@duomocomunicacion.com



'/>"/>
SOURCE Health Robotics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Southland ... line of classic American timber frame barn kits, which can be found on its ... inspired by historic American barn plans, and they highlight the craftsmanship of timber post ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke survivors ... sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics had ... with hemiplegia due to stroke. , Ekso Bionics has now received clearance from the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
Breaking Medicine Technology: